/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Diego, CAMaxwell Biomedical is developing a first-of-its-kind device-based solution designed to maintain sinus rhythm in patients with Atrial Fibrillation (AFib).MAXWELLBIOMEDICAL.COM © Copyright RiverVest® All Rights Reserved....

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Austin, TXAlleviant Medical, Inc. is a medical device company developing a minimally invasive, implant-free interatrial shunt device under clinical investigation for the treatment of chronic heart failure. The Alleviant System was granted U.S. FDA Breakthrough...

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Diego, CAAvalyn is a biopharma company developing improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The lead asset is inhaled pirfenidone (Aerodone™) for the treatment of...

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} St. Louis, MOWith RiverVest as a founder, Arch Oncology is focused on the discovery and development of best-in-class antibody therapies for the treatment of patients with solid-tumor and certain blood cancers. Arch Oncology’s next-generation...

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Boston, MAXilio is an oncology company developing highly-potent, tumor-selective immunotherapies to improve patient outcomes. With an anti-CTLA4 antibody as validation, the company’s technology is also being applied to cytokines, which currently have limited or...

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Minneapolis, MNCardialen is an early-stage medical device company dedicated to advancing implantable cardioversion and defibrillation therapy to restore normal heart rhythm using significantly lower energy than existing therapies. Cardialen’s MultiPulse™ Therapy (MPT) is currently...

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Francisco, CAInterVene's mission is to provide the first effective and widely-utilized therapy for patients suffering from the painful and costly symptoms of Chronic Venous Insufficiency (CVI) due to deep vein reflux (DVR). InterVene,...

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Seattle, WAOncoResponse is leveraging a proprietary human antibody platform to discover novel targets and identify fully-human monoclonal antibodies as therapeutics for the treatment of cancer, potentially extending cures to patients who otherwise would not...

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} St. Louis, MOOxaluRx is a preclinical company developing a small molecule, oral therapy to treat primary hyperoxaluria, a rare orphan metabolic disease. This rare form of hyperoxaluria is due exclusively to a genetic defect...

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Diego, CAIPO April 2021 (NASDAQ: RPHM)Reneo, a RiverVest-founded company, is a clinical-stage pharmaceutical company focused on the development of therapies for patients with genetic mitochondrial diseases. Many of these diseases are associated with...

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Philadelphia, PAScout is focused on delivering a new generation of gene therapies for pets to significantly improve the standard-of-care for multiple conditions. The technology approach is to express an appropriate level of a therapeutic...

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Francisco, CAIPO October 2020 (NASDAQ: SPRB)Spruce is developing novel therapies for rare endocrine diseases. The company’s lead product candidate for the treatment of congenital adrenal hyperplasia (CAH) is intended to correct hormone imbalances,...

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Minneapolis, MNVentureMed develops and markets innovative medical devices for the treatment of peripheral vascular disease (PAD) and stenosis of arteriovenous (AV) fistulas and grafts, serious conditions leading to reduced blood flow and many complications....

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} St. Louis, MOWugen is developing a novel chimeric antigen receptor (CAR-T) therapy platform for T-cell malignancies. Wugen’s state-of-the-art gene editing and CAR-T cell technology enable “off-the-shelf” therapies that would avoid rejection by the recipient....

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Francisco, CAIPO July 2018 (NASDAQ: ALLK)Allakos is a clinical-stage biotechnology company developing therapeutic antibodies targeting a broad range of allergic, inflammatory, and proliferative diseases. The Company’s lead antibody, AK002, targets Siglec-8, an inhibitory receptor...

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Francisco, CAIPO July 2019 (NASDAQ: MIRM)Mirum was formed, with support from RiverVest, to develop the compound previously developed by Lumena (see Lumena discussion above).  After Takeda’s acquisition of Shire, the compound, now called...